Bausch Health, Teva Hit With Xifaxan Pay-for-Delay Scheme Claims

Bausch Health Co. and Teva Pharmaceutical Industries Ltd. were sued in federal court by a health and welfare benefit fund, which claimed the companies conspired to delay the generic version of the blockbuster Xifaxan drug.

Plaintiff Rhode Island Laborers Health & Welfare Fund alleges Bausch paid to delay Teva’s entry into the market for a generic form of Xifaxan until January 2028, causing the fund to pay higher prices for the medication, according to a proposed class action filed Monday in the US District Court for the District of Rhode Island.

Xifaxan is a branded Bausch drug for irritable bowel ...